文献速递前列腺癌

局限性前列腺癌患者接受立体定向体部放疗、常规分割外照射放疗与主动监测后的患者报告生活质量比较

Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
PubMed 文献 · Eur Urol · 2019-03-08

基于人群的前瞻性队列纳入680例新诊断局限性前列腺癌男性,2011至2013年入组,比较立体定向体部放疗(SBRT)、未联合雄激素剥夺治疗的常规分割外照射放疗(EBRT)与主动监测(AS)的患者报告生活质量。EBRT患者在3个月时泌尿梗阻/刺激症状和性功能障碍更差、3和24个月时肠道症状更差;SBRT患者各领域各时间点与AS相似,但样本量小,不能排除SBRT后性功能和尿失禁更差。

要点

  • EBRT患者3个月时泌尿梗阻/刺激症状和性功能障碍较AS更差。
  • EBRT患者3和24个月时肠道症状较AS更差。
  • SBRT各领域各时间点与AS相似,但样本量小不能排除性功能和尿失禁更差。

核心结论

  • 在非随机局限性前列腺癌男性队列中,SBRT在2年随访内似乎带来良好的生活质量结果,但不能完全排除与AS相比性功能和尿失禁更差。
  • 需要更大样本、更长随访的研究来证实这些发现。

研究设计与样本

  • 基于人群的前瞻性队列,纳入680例新诊断局限性前列腺癌男性,2011至2013年入组。
  • 干预为SBRT、未联合雄激素剥夺治疗的EBRT或AS。
  • 采用经验证的前列腺癌症状指数在治疗前(基线)及治疗后3、12、24个月前瞻性评估生活质量,含性功能障碍、泌尿梗阻/刺激、尿失禁、肠道问题四个领域。
  • 通过logistic回归模型进行倾向加权以平衡基线特征,以AS患者为对照组比较EBRT和SBRT患者的平均生活质量评分。

主要发现

  • 与AS患者相比,EBRT患者在3个月时泌尿梗阻/刺激症状和性功能障碍更差。
  • 与AS患者相比,EBRT患者在3和24个月时肠道症状更差。
  • SBRT患者在所有领域和所有时间点与AS患者评分相似。
  • 由于样本量小,不能排除SBRT患者性功能和尿失禁更差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量小,不能排除SBRT患者性功能和尿失禁更差。
  • 需要进一步研究评估长期结局。
  • 需要更大样本、更长随访的研究来证实这些发现。
  • 为非随机队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence supporting the efficacy of stereotactic body radiotherapy (SBRT) for localized prostate cancer is accumulating, but comparative studies of patient-reported quality of life (QOL) following SBRT versus conventionally fractionated external beam radiotherapy (EBRT) or active surveillance (AS) are limited. OBJECTIVE: To compare QOL of patients pursuing SBRT and EBRT versus AS. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort of 680 men with newly diagnosed localized prostate cancer was prospectively enrolled from 2011 to 2013. INTERVENTION: SBRT, EBRT without androgen deprivation therapy, or AS. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: QOL was prospectively assessed before treatment (baseline), and at 3, 12, and 24mo after treatment using the validated Prostate Cancer Symptom Indices, which contain four domains: sexual dysfunction, urinary obstruction/irritation, urinary incontinence, and bowel problems. Propensity weighting via logistic regression models was used to balance baseline characteristics, and the mean QOL scores of EBRT and SBRT patients were compared against AS patients as the control group. RESULTS AND LIMITATIONS: Compared with AS patients, EBRT patients had worse urinary obstructive/irritative symptoms and sexual dysfunction at 3mo, and worse bowel symptoms at 3 and 24mo. SBRT patients had similar scores as AS patients in all domains and across all time points; however, due to small sample size, worse sexual function and urinary incontinence in SBRT patients cannot be ruled out. Further research is needed to assess long-term outcomes. CONCLUSIONS: In a nonrandomized cohort of men with localized prostate cancer, SBRT appeared to result in favorable QOL results through 2yr of follow-up, but worse sexual function and urinary incontinence compared with AS cannot be ruled out completely. Larger studies with longer follow-up are needed to confirm these findings. PATIENT SUMMARY: Stereotactic body radiotherapy (SBRT) and active surveillance appear to have similar quality of life outcomes through 2yr, although worse sexual function and urinary incontinence from SBRT cannot be ruled out completely.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Moon DH, Basak RS, Usinger DS, et al. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer. Eur Urol. 2019. PMID: 30857758. doi:10.1016/j.eururo.2019.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。